Hangzhou, China, January 26, 2026 — HealZen Therapeutics Co., Ltd. today announced a new strategic partnership with a U.S. biotech company to advance Degrader–Antibody Conjugate (DAC) therapeutics, marking the first cross-border collaboration for this modality. This partnership represents an important milestone for HealZen and is a testament to China's growing influence in global drug innovation.

Under the agreement, HealZen will retain Greater China rights for the partnered DAC programs and will receive an upfront payment, milestone payments, tiered sales royalties and potential sublicense income.

This partnership is HealZen’s second out-licensing deal in the targeted protein degradation (TPD) space, following the BTK degrader agreement with Johnson & Johnson announced in early 2025—further underscoring its robust pipeline and leadership in TPD innovation.

 Additional details on the strategic collaboration will be disclosed at a mutually agreed time.